



IFW

Dkt. 2609/60726-AZ/JPW/GJG/NDP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Moses Rodriguez and Daren Ure

Serial No. : 10/776,442 Group Art Unit: 1614

Filing Date : February 10, 2004

For : TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES BY
ANTIBODIES AGAINST GLATIRAMER ACETATE

1185 Avenue of the Americas
New York, NY 10036
October 4, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below. Copies of the references listed below as items 1-10 are attached hereto as **Exhibits 1-10**.

This Second Supplemental Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Second Information Disclosure Statement should be entered and considered.

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: 10/776,442
Filed : February 10, 2004
Page 2

Applicants point out that item 1 below is Supplementary EPO Search Report issued August 25, 2005 in connection with counterpart EP Application No. 01 95 2169. Items 2 and 4-10 below were cited in the Supplementary EPO Search Report listed as item 1. Accordingly, applicants request that this Second Supplemental Information Disclosure Statement be considered.

1. Supplementary European Search Report issued on August 25, 2005 in connection with European Patent Application No. 1 292 279, published March 19, 2003 (**Exhibit 1**);
2. EP 1 292 279, published on March 19, 2003, which corresponds to WO 01/93828 A1 attached as Exhibit 3. A printout from the European Patent Office website states that the two publications are identical (**Exhibit 2**);
3. PCT International Publication No. WO 01/93828 A1, (PCT/US01/18248), published December 13, 2001 (**Exhibit 3**);
4. "About Copaxone", Internet Article
URL:<http://www.mswatch.com/therapy/section.aspx?SectionId=789eabf5-3a07-4dff-a7ee-0d4ad1381a6d> (**Exhibit 4**);
5. Racadot, E. et al. (1993) "Treatment of Multiple Sclerosis with Anti-CD4 Monoclonal Antibody" J. of Autoimmunity 6:771-786 (**Exhibit 5**);
6. Rodriguez, M. et al. (1996) "Immunoglobulins Reactive with Myelin Basic Protein Promote CNS Remyelination" Neurology 46:538-545 (**Exhibit 6**);

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: 10/776,442
Filed : February 10, 2004
Page 3

7. Ure, D.R. et al. (2002) "Polyreactive Antibodies to Glatiramer Acetate Promote Myelin Repair in Murine Model of Demyelinating Disease" FASEB Journal 16:1260-1262 (**Exhibit 7**);
8. Vandembark, A.A. et al. (1985) "Specificity of T Lymphocyte Lines for Peptides of Myelin Basic Protein" The J. of Immunology 135:229-233 (**Exhibit 8**);
9. Weilbach, F.X. et al. (1999) "Disease Modifying Treatments for Multiple Sclerosis" CNS Drugs 11(2):133-167 (**Exhibit 9**);
10. Zhang, J.W. et al. (1989) "Murine Monoclonal Anti-Myelin Basic Protein (MBP) Antibodies Inhibit Proliferation and Cytotoxicity of MBP-Specific Human T Cell Clones" J. of Neuroimmunology 24:87-94 (**Exhibit 10**);


Applicants request that the Examiner review the publication and make it of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: 10/776,442
Filed : February 10, 2004
Page 4

No fee is deemed necessary in connection with the filing of this Second Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

 10/4/05
John P. White Date

Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

Applicants: Moses Rodriguez et al.
Serial No.: 10/776, 442
Filed: February 10, 2004
Exhibit A